<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320823</url>
  </required_header>
  <id_info>
    <org_study_id>TP-CLN-100467</org_study_id>
    <nct_id>NCT04320823</nct_id>
  </id_info>
  <brief_title>IMPACT (Improving Plasma Collection) Clinical Trial</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Prospective, Randomized, Controlled, Multicenter Clinical Trial to Demonstrate the Safety and Effectiveness of the NexSys® PCS Plasma Collection System With the Percent Plasma Nomogram (PPN) Feature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haemonetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haemonetics Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, randomized, controlled clinical trial to study the safety and&#xD;
      effectiveness of a novel plasma collection system software.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multi-center, randomized, controlled clinical trial that will be conducted at&#xD;
      three source plasma collection centers throughout the United States. The objective of the&#xD;
      trial is to study the safety and effectiveness of a novel plasma collection nomogram run on&#xD;
      the bi-directionally integrated Haemonetics NexSys PCS® and Haemonetics NexLynk DMS® plasma&#xD;
      collection system. Subjects will be randomized into an intervention and control arm. The&#xD;
      control arm will donate plasma using the current software. The intervention arm will donate&#xD;
      plasma using a novel software that supports a more individualized collection approach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Actual">April 27, 2020</completion_date>
  <primary_completion_date type="Actual">March 27, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-arm, randomized, controlled trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Significant Hypotensive Adverse Events</measure>
    <time_frame>Up to approximately 3 months (total trial duration during which donors could donate), depending on time of enrollment into the trial.</time_frame>
    <description>The incidence rate of at least one significant hypotensive (vasovagal/hypovolemia) adverse event according to the plasma center adverse event reporting system, based on IQPP definitions of Signs/Symptoms/Findings.&#xD;
Significant adverse events are defined as such events that fulfill the Signs/Symptoms/Findings of IQPP Donor Adverse Events (DAE) classifications 1.2 through 1.6 per the modified, symptoms-based approach following the plasma center adverse event reporting system.&#xD;
A Model Based Prediction method was used for this outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Severe Hypotensive Adverse Events</measure>
    <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
    <description>Incidence rate of severe hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, per donation in donors undergoing plasmapheresis.&#xD;
*Only two severe (1.5) adverse events were observed: one in the experimental group and one in the control group. As the secondary analysis for severe hypotensive adverse events was to be conducted only if there were more than 2 severe hypotensive (vasovagal/hypovolemia) adverse events in any of the two study groups, no formal statistical analysis was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Significant Hypotensive Adverse Events Relative to Volume</measure>
    <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
    <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, relative to the actual plasma volume collected.&#xD;
*The outcome is reported as the expected number of significant hypotensive adverse events per 10,000 L of collected plasma. This outcome was calculated using the total number of significant hypotensive adverse events and the total amount of plasma collected, then normalized to 10,000 L of collected plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Start of Collection to First Significant Hypotensive Adverse Event</measure>
    <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
    <description>Time from start of plasmapheresis &quot;Begin Draw&quot; to the first significant hypotensive (vasovagal/hypovolemia) adverse event according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Significant Hypotensive Adverse Events Relative to Bodyweight</measure>
    <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
    <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, in the subgroups of donors with a bodyweight of less than or equal to 130 lbs and those greater than 130 lbs.&#xD;
*Note: Due to the absence of AE in the subgroup of donors with bodyweight of ≤130 lbs, no formal statistical analysis was performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Significant Hypotensive Adverse Events Relative to BMI</measure>
    <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
    <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, in the subgroups of donors with a body mass index (BMI) of less than or equal to 30 and of those greater than 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Significant Hypotensive Adverse Events Relative to Donor Status</measure>
    <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
    <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, in the subgroups of donors defined by their respective status as a first-time donor or repeat donor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Significant Hypotensive Adverse Events Relative to Gender</measure>
    <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
    <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, in the subgroups of donors defined by their gender.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Volume</measure>
    <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
    <description>Total plasma volume collected per procedure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3443</enrollment>
  <condition>Apheresis Related Hypotension</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Updated Plasma Collection Feature</intervention_name>
    <description>Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Current Plasma Collection Approach</intervention_name>
    <description>Plasma collection using the current collection approach.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Donors must be qualified to donate plasma per individual site's screening procedures&#xD;
             which are in compliance with IQPP standards. If donors do not meet inclusion criteria&#xD;
             at subsequent donations but have already been enrolled in the clinical trial, they are&#xD;
             eligible to remain in the clinical trial and to donate plasma within the clinical&#xD;
             trial once they meet eligibility criteria again, except if they fulfill any of the&#xD;
             exclusion criteria listed below.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All subjects meeting any of the exclusion criteria listed below will be permanently&#xD;
             excluded from the clinical trial.&#xD;
&#xD;
               -  Subject not able or willing to give consent to participate in the clinical trial.&#xD;
&#xD;
               -  Subject donated plasma outside of the present clinical trial after enrolling in&#xD;
                  this clinical trial.&#xD;
&#xD;
               -  Subjects are withdrawn from the clinical trial due to safety concerns by the&#xD;
                  qualified healthcare providers.&#xD;
&#xD;
               -  In addition, all donors for whom a BMI for use in the PPN feature cannot be&#xD;
                  reliably calculated will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Donors must indicate their biological gender.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan F Leitman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health (NIH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Octapharma Plasma</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Plasma</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Plasma</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <results_first_submitted>February 15, 2021</results_first_submitted>
  <results_first_submitted_qc>March 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2021</results_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasmapheresis (Source plasma collection)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT04320823/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT04320823/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental Group</title>
          <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1717"/>
                <participants group_id="P2" count="1726"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1717">Includes 47 donors who withdrew from the study after one or more donations.</participants>
                <participants group_id="P2" count="1726">Includes 38 donors who withdrew from the study after one or more donations.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental Group</title>
          <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1717"/>
            <count group_id="B2" value="1726"/>
            <count group_id="B3" value="3443"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Donations</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11362"/>
            <count group_id="B2" value="11775"/>
            <count group_id="B3" value="23137"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1717"/>
                <count group_id="B2" value="1726"/>
                <count group_id="B3" value="3443"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="11362"/>
                <count group_id="B2" value="11775"/>
                <count group_id="B3" value="23137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="11.69"/>
                    <measurement group_id="B2" value="35.4" spread="11.10"/>
                    <measurement group_id="B3" value="35.4" spread="11.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1717"/>
                <count group_id="B2" value="1726"/>
                <count group_id="B3" value="3443"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="11362"/>
                <count group_id="B2" value="11775"/>
                <count group_id="B3" value="23137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="605"/>
                    <measurement group_id="B2" value="601"/>
                    <measurement group_id="B3" value="1206"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1112"/>
                    <measurement group_id="B2" value="1125"/>
                    <measurement group_id="B3" value="2237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="0"/>
                <count group_id="B2" value="0"/>
                <count group_id="B3" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="11362"/>
                <count group_id="B2" value="11775"/>
                <count group_id="B3" value="23137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1717"/>
                <count group_id="B2" value="1726"/>
                <count group_id="B3" value="3443"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="11362"/>
                <count group_id="B2" value="11775"/>
                <count group_id="B3" value="23137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1717"/>
                    <measurement group_id="B2" value="1726"/>
                    <measurement group_id="B3" value="3443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1717"/>
                <count group_id="B2" value="1726"/>
                <count group_id="B3" value="3443"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="11362"/>
                <count group_id="B2" value="11775"/>
                <count group_id="B3" value="23137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="7.74"/>
                    <measurement group_id="B2" value="31.8" spread="7.75"/>
                    <measurement group_id="B3" value="32.0" spread="7.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1717"/>
                <count group_id="B2" value="1726"/>
                <count group_id="B3" value="3443"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="11362"/>
                <count group_id="B2" value="11775"/>
                <count group_id="B3" value="23137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207.5" spread="50.99"/>
                    <measurement group_id="B2" value="206.1" spread="51.33"/>
                    <measurement group_id="B3" value="206.8" spread="51.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>in</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1717"/>
                <count group_id="B2" value="1726"/>
                <count group_id="B3" value="3443"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="11362"/>
                <count group_id="B2" value="11775"/>
                <count group_id="B3" value="23137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="3.60"/>
                    <measurement group_id="B2" value="67.5" spread="3.62"/>
                    <measurement group_id="B3" value="67.5" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Donor Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1717"/>
                <count group_id="B2" value="1726"/>
                <count group_id="B3" value="3443"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="11362"/>
                <count group_id="B2" value="11775"/>
                <count group_id="B3" value="23137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Repeat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1608"/>
                    <measurement group_id="B2" value="1618"/>
                    <measurement group_id="B3" value="3226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First-Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematocrit</title>
          <units>percentage of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="1717"/>
                <count group_id="B2" value="1726"/>
                <count group_id="B3" value="3443"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="B1" value="11362"/>
                <count group_id="B2" value="11775"/>
                <count group_id="B3" value="23137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="3.81"/>
                    <measurement group_id="B2" value="45.4" spread="3.77"/>
                    <measurement group_id="B3" value="45.5" spread="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Significant Hypotensive Adverse Events</title>
        <description>The incidence rate of at least one significant hypotensive (vasovagal/hypovolemia) adverse event according to the plasma center adverse event reporting system, based on IQPP definitions of Signs/Symptoms/Findings.&#xD;
Significant adverse events are defined as such events that fulfill the Signs/Symptoms/Findings of IQPP Donor Adverse Events (DAE) classifications 1.2 through 1.6 per the modified, symptoms-based approach following the plasma center adverse event reporting system.&#xD;
A Model Based Prediction method was used for this outcome.</description>
        <time_frame>Up to approximately 3 months (total trial duration during which donors could donate), depending on time of enrollment into the trial.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Significant Hypotensive Adverse Events</title>
          <description>The incidence rate of at least one significant hypotensive (vasovagal/hypovolemia) adverse event according to the plasma center adverse event reporting system, based on IQPP definitions of Signs/Symptoms/Findings.&#xD;
Significant adverse events are defined as such events that fulfill the Signs/Symptoms/Findings of IQPP Donor Adverse Events (DAE) classifications 1.2 through 1.6 per the modified, symptoms-based approach following the plasma center adverse event reporting system.&#xD;
A Model Based Prediction method was used for this outcome.</description>
          <units>% of significant hypotensive AEs</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Donations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1717"/>
                <count group_id="O2" value="1726"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11362"/>
                <count group_id="O2" value="11775"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".035" lower_limit=".010" upper_limit=".094"/>
                    <measurement group_id="O2" value=".051" lower_limit=".020" upper_limit=".114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Severe Hypotensive Adverse Events</title>
        <description>Incidence rate of severe hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, per donation in donors undergoing plasmapheresis.&#xD;
*Only two severe (1.5) adverse events were observed: one in the experimental group and one in the control group. As the secondary analysis for severe hypotensive adverse events was to be conducted only if there were more than 2 severe hypotensive (vasovagal/hypovolemia) adverse events in any of the two study groups, no formal statistical analysis was performed.</description>
        <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Severe Hypotensive Adverse Events</title>
          <description>Incidence rate of severe hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, per donation in donors undergoing plasmapheresis.&#xD;
*Only two severe (1.5) adverse events were observed: one in the experimental group and one in the control group. As the secondary analysis for severe hypotensive adverse events was to be conducted only if there were more than 2 severe hypotensive (vasovagal/hypovolemia) adverse events in any of the two study groups, no formal statistical analysis was performed.</description>
          <units>Severe Hypotensive Adverse Events</units>
          <param>Number</param>
          <units_analyzed>Donations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1717"/>
                <count group_id="O2" value="1726"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11362"/>
                <count group_id="O2" value="11775"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Significant Hypotensive Adverse Events Relative to Volume</title>
        <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, relative to the actual plasma volume collected.&#xD;
*The outcome is reported as the expected number of significant hypotensive adverse events per 10,000 L of collected plasma. This outcome was calculated using the total number of significant hypotensive adverse events and the total amount of plasma collected, then normalized to 10,000 L of collected plasma.</description>
        <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
        <population>This analysis was performed on the PP (per protocol) population, defined as all donations where the apheresis procedure was successfully completed collecting at least 90% of target plasma volume as well as all donations associated with a significant hypotensive (vasovagal/hypovolemia) adverse event according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Significant Hypotensive Adverse Events Relative to Volume</title>
          <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, relative to the actual plasma volume collected.&#xD;
*The outcome is reported as the expected number of significant hypotensive adverse events per 10,000 L of collected plasma. This outcome was calculated using the total number of significant hypotensive adverse events and the total amount of plasma collected, then normalized to 10,000 L of collected plasma.</description>
          <population>This analysis was performed on the PP (per protocol) population, defined as all donations where the apheresis procedure was successfully completed collecting at least 90% of target plasma volume as well as all donations associated with a significant hypotensive (vasovagal/hypovolemia) adverse event according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings.</population>
          <units>No. of AEs per 10,000L of Plasma</units>
          <param>Number</param>
          <units_analyzed>Donations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1684"/>
                <count group_id="O2" value="1689"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10984"/>
                <count group_id="O2" value="11458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27"/>
                    <measurement group_id="O2" value="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Start of Collection to First Significant Hypotensive Adverse Event</title>
        <description>Time from start of plasmapheresis &quot;Begin Draw&quot; to the first significant hypotensive (vasovagal/hypovolemia) adverse event according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings.</description>
        <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Start of Collection to First Significant Hypotensive Adverse Event</title>
          <description>Time from start of plasmapheresis &quot;Begin Draw&quot; to the first significant hypotensive (vasovagal/hypovolemia) adverse event according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Donations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1717"/>
                <count group_id="O2" value="1726"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11362"/>
                <count group_id="O2" value="11775"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.41" spread="16.52"/>
                    <measurement group_id="O2" value="51.59" spread="17.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Significant Hypotensive Adverse Events Relative to Bodyweight</title>
        <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, in the subgroups of donors with a bodyweight of less than or equal to 130 lbs and those greater than 130 lbs.&#xD;
*Note: Due to the absence of AE in the subgroup of donors with bodyweight of ≤130 lbs, no formal statistical analysis was performed.</description>
        <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
        <population>The total number of Participants Analyzed is more than the total population of donors in the study as some donors moved from one bodyweight group to the other throughout their participation in the study. Therefore, this analysis was done at the donation level, based on the bodyweight of each donor at the time of each donation. The number of donations are therefore also listed.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group With Weight ≤ 130 Lbs</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
          </group>
          <group group_id="O2">
            <title>Control Group With Weight ≤ 130 Lbs</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
          </group>
          <group group_id="O3">
            <title>Experimental Group With Weight &gt; 130 Lbs</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
          </group>
          <group group_id="O4">
            <title>Control Group With Weight &gt; 130 Lbs</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Significant Hypotensive Adverse Events Relative to Bodyweight</title>
          <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, in the subgroups of donors with a bodyweight of less than or equal to 130 lbs and those greater than 130 lbs.&#xD;
*Note: Due to the absence of AE in the subgroup of donors with bodyweight of ≤130 lbs, no formal statistical analysis was performed.</description>
          <population>The total number of Participants Analyzed is more than the total population of donors in the study as some donors moved from one bodyweight group to the other throughout their participation in the study. Therefore, this analysis was done at the donation level, based on the bodyweight of each donor at the time of each donation. The number of donations are therefore also listed.</population>
          <units>% of significant hypotensive AEs</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Donations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="1671"/>
                <count group_id="O4" value="1689"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="287"/>
                <count group_id="O3" value="11111"/>
                <count group_id="O4" value="11488"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value=".036" lower_limit=".010" upper_limit=".096"/>
                    <measurement group_id="O4" value=".052" lower_limit=".020" upper_limit=".117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Significant Hypotensive Adverse Events Relative to BMI</title>
        <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, in the subgroups of donors with a body mass index (BMI) of less than or equal to 30 and of those greater than 30.</description>
        <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
        <population>The total number of Participants Analyzed is more than the total population of donors in the study as some donors moved from one BMI group to the other throughout their participation in the study. Therefore, this analysis was done at the donation level, based on the BMI of each donor at the time of each donation. The number of donations are therefore also listed.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group With BMI ≤ 30</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
          </group>
          <group group_id="O2">
            <title>Control Group With BMI ≤ 30 Lbs</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
          </group>
          <group group_id="O3">
            <title>Experimental Group With BMI &gt; 30</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
          </group>
          <group group_id="O4">
            <title>Control Group With BMI &gt; 30</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Significant Hypotensive Adverse Events Relative to BMI</title>
          <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, in the subgroups of donors with a body mass index (BMI) of less than or equal to 30 and of those greater than 30.</description>
          <population>The total number of Participants Analyzed is more than the total population of donors in the study as some donors moved from one BMI group to the other throughout their participation in the study. Therefore, this analysis was done at the donation level, based on the BMI of each donor at the time of each donation. The number of donations are therefore also listed.</population>
          <units>% of significant hypotensive AEs</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Donations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="802"/>
                <count group_id="O2" value="872"/>
                <count group_id="O3" value="1000"/>
                <count group_id="O4" value="965"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4638"/>
                <count group_id="O2" value="4981"/>
                <count group_id="O3" value="6724"/>
                <count group_id="O4" value="6794"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".043" lower_limit=".001" upper_limit=".168"/>
                    <measurement group_id="O2" value=".020" lower_limit="-.009" upper_limit=".126"/>
                    <measurement group_id="O3" value=".03" lower_limit=".001" upper_limit=".116"/>
                    <measurement group_id="O4" value=".074" lower_limit=".026" upper_limit=".178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Significant Hypotensive Adverse Events Relative to Donor Status</title>
        <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, in the subgroups of donors defined by their respective status as a first-time donor or repeat donor.</description>
        <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group - First-Time Donor</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
          </group>
          <group group_id="O2">
            <title>Control Group - First-Time Donor</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
          </group>
          <group group_id="O3">
            <title>Experimental Group - Repeat Donor</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
          </group>
          <group group_id="O4">
            <title>Control Group - Repeat Donor</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Significant Hypotensive Adverse Events Relative to Donor Status</title>
          <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, in the subgroups of donors defined by their respective status as a first-time donor or repeat donor.</description>
          <units>% of significant hypotensive AEs</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Donations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="1608"/>
                <count group_id="O4" value="1618"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="405"/>
                <count group_id="O3" value="10943"/>
                <count group_id="O4" value="11370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1.095"/>
                    <measurement group_id="O2" value=".247" lower_limit="0" upper_limit="1.531"/>
                    <measurement group_id="O3" value=".037" lower_limit=".011" upper_limit=".098"/>
                    <measurement group_id="O4" value=".044" lower_limit=".016" upper_limit=".106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Significant Hypotensive Adverse Events Relative to Gender</title>
        <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, in the subgroups of donors defined by their gender.</description>
        <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group - Female Donor</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
          </group>
          <group group_id="O2">
            <title>Control Group - Female Donor</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
          </group>
          <group group_id="O3">
            <title>Experimental Group - Male Donor</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
          </group>
          <group group_id="O4">
            <title>Control Group - Male Donor</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Significant Hypotensive Adverse Events Relative to Gender</title>
          <description>Incidence rate of significant hypotensive (vasovagal/hypovolemia) adverse events according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings, in the subgroups of donors defined by their gender.</description>
          <units>% of significant hypotensive AEs</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Donations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="605"/>
                <count group_id="O2" value="601"/>
                <count group_id="O3" value="1112"/>
                <count group_id="O4" value="1125"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3485"/>
                <count group_id="O2" value="3739"/>
                <count group_id="O3" value="7877"/>
                <count group_id="O4" value="8036"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".048" lower_limit=".014" upper_limit=".130"/>
                    <measurement group_id="O2" value=".07" lower_limit=".028" upper_limit=".155"/>
                    <measurement group_id="O3" value=".028" lower_limit=".010" upper_limit=".066"/>
                    <measurement group_id="O4" value=".040" lower_limit=".018" upper_limit=".082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Volume</title>
        <description>Total plasma volume collected per procedure.</description>
        <time_frame>Up to approximately 3 months, depending on time of enrollment into the trial.</time_frame>
        <population>This analysis was performed on the PP (per protocol) population, defined as all donations where the apheresis procedure was successfully completed collecting at least 90% of target plasma volume as well as all donations associated with a significant hypotensive (vasovagal/hypovolemia) adverse event according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Volume</title>
          <description>Total plasma volume collected per procedure.</description>
          <population>This analysis was performed on the PP (per protocol) population, defined as all donations where the apheresis procedure was successfully completed collecting at least 90% of target plasma volume as well as all donations associated with a significant hypotensive (vasovagal/hypovolemia) adverse event according to the plasma center adverse event reporting system, based on the IQPP definitions of Signs/Symptoms/Findings.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Donations</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1684"/>
                <count group_id="O2" value="1689"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Donations</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10984"/>
                <count group_id="O2" value="11458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="841.69" lower_limit="636" upper_limit="1000"/>
                    <measurement group_id="O2" value="777.84" lower_limit="625" upper_limit="801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were monitored and collected for all donations of study participants throughout the entire duration of the clinical trial, approximately 3 months.</time_frame>
      <desc>For the purposes of this clinical trial, all adverse events (AEs) were defined and categorized according to established local guidelines and operating procedures and in accordance with IQPP definitions of Signs/Symptoms/Findings.</desc>
      <group_list>
        <group group_id="E1">
          <title>Experimental Group</title>
          <description>Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.&#xD;
Updated Plasma Collection Feature: Plasma collection using a novel, patented system that supports a more individualized collection approach.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.&#xD;
Current Plasma Collection Approach: Plasma collection using the current collection approach.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1717"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1726"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1717"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1726"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="1717"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="1726"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>IQPP 7.1 Allergic: Local</sub_title>
                <description>May include Itching; Rash/Hives; or Redness.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1717"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1726"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>IQPP 4.2 Citrate Reaction: Moderate</sub_title>
                <description>May include Carpopedal Spasms; Chest Pressure; Cold Extremities; Chills; Muscle Tightness/Cramping; Nausea; Pallor, Pale Skin or Lips; Shortness of Breath; Sneezing/Nasal Congestion; Tetany (Transient); Tremors; Twitching; or Vomiting.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1717"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1726"/>
              </event>
              <event>
                <sub_title>IQPP 4.1 Citrate Reaction: Minor</sub_title>
                <description>May include Metallic Taste; Paresthesia (Perioral - Lips (Tingling/Numbness); or Paresthesia (Peripheral - Hands/Feet Tingling/Numbness).</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1717"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1726"/>
              </event>
              <event>
                <sub_title>IQPP 3.3 Local Injury Related to Phlebotomy: Hematoma/Bruise (complicated)</sub_title>
                <description>May include Paresthesias, Numbness/Tingling of Fingers, Hand, or Arm; Pressure; Redness; Restricted Movement; Shooting Pain Down Arm; Significant Pain; Skin Discoloration; Swelling; Tenderness; Warmth; or Weakness of Arm.</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1717"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="1726"/>
              </event>
              <event>
                <sub_title>IQPP 3.2 Local Injury Related to Phlebotomy: Hematoma/Bruise (uncomplicated)</sub_title>
                <description>May include Mild Pain; No Restriction of Movement; Skin Discoloration; or Swelling.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1717"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1726"/>
              </event>
              <event>
                <sub_title>3.1 Local Injury Related to Phlebotomy: Nerve Irritation</sub_title>
                <description>May include Immediate Intense Pain at Site; Paresthesias, Numbness/Tingling of Fingers, Hand, or Arm; Shooting Pain Down Arm; or Weakness of Arm.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1717"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1726"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>IQPP 9.1 Other</sub_title>
                <description>A reaction that does not fall into any other IQPP category. In this event, donor reported feeling dizzy during standard screening, prior to any plasmapheresis or study activities.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1717"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1726"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>IQPP 8.1 Hyperventilation</sub_title>
                <description>May include Anxiousness / Anxiety; Carpopedal Spasms; Chest Tightness; Dry Mouth; Paresthesia (Perioral -Tingling/Numbness); Paresthesia (Peripheral - Hands/Feet); Respiration, Rapid; Restlessness; Shaking; Shortness of Breath; or Tetany.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1717"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1726"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>IQPP 1.5 Hypotensive (Vasovagal/Hypovolemia); Severe (With or Without LOC)</sub_title>
                <description>This reaction may or may not include LOC and may include Chest Pain, Convulsions/Seizures, Loss of Bladder/Bowel</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1717"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1726"/>
              </event>
              <event>
                <sub_title>IQPP 1.4 Hypotensive (Vasovagal/Hypovolemia): LOC (prolonged)</sub_title>
                <description>In this reaction, LOC lasts approximately sixty seconds or longer.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1717"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1726"/>
              </event>
              <event>
                <sub_title>IQPP 1.3 Hypotensive: LOC (brief)</sub_title>
                <description>In this reaction, LOC lasts approximately less than sixty seconds.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1717"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1726"/>
              </event>
              <event>
                <sub_title>IQPP 1.2 Hypotensive: Prefaint, No LOC (Moderate):</sub_title>
                <description>This reaction includes vomiting.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1717"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1726"/>
              </event>
              <event>
                <sub_title>IQPP 1.1 Hypotensive: Prefaint, No LOC (Minor)</sub_title>
                <description>May include one or more of minor symptoms, e.g., abdominal cramps, auditory disturbance, chills or shivering, clammy, cold extremities, dizziness, nausea, sweating, weakness.</description>
                <counts group_id="E1" events="63" subjects_affected="56" subjects_at_risk="1717"/>
                <counts group_id="E2" events="42" subjects_affected="38" subjects_at_risk="1726"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Site and Investigator shall not publish, disclose, present or use for instruction any Results arising out of its conduct of the Study at the Site without the express prior written consent of Sponsor, except to the extent required by applicable law. Sponsor shall have final review and approval rights for any authorized publication by Investigator, including but not limited to publication strategy, publication decisions, publication content and authorship decisions.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jan Hartmann, MD, Vice President of Medical Affairs and Clinical Development</name_or_title>
      <organization>Haemonetics Corporation</organization>
      <phone>(781) 348 7396</phone>
      <email>Jan.Hartmann@haemonetics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

